

Press release

Lund 15 October 2021

Scandinavian ChemoTech's subsidiary Vetique signs agreement with Evidensia Specialistdjursjukhuset Helsingborg

Today, Vetique signed a collaboration agreement that gives the veterinary hospital access to a vetIQure™ in order to start treatments of animals suffering from cancer. Initially, smaller animals, such as dogs and cats, will be treated.

Vetique continues to, through intensive marketing during the spring and summer, create attention and interest among veterinarians in both Europe and the United States. It is beginning to become clear that many veterinarians with previous experience in electrochemotherapy see vetIQure's unique and dynamic TSE technology as very interesting and significant.

"We are very pleased to be able to start TSE treatments at Evidensia Specialistdjursjukhuset Helsingborg and look forward to a successful collaboration in order to reduce suffering for many animals, while providing commercial success for both parties" - says Anders Johnsson, business area manager for Vetique AB

For more information regarding Evidensia Specialistdjursjukhuset Helsingborg (in Swedish):

<https://www.evidensia.se/>

<https://evidensia.se/klinik/evidensia-specialistdjursjukhuset-helsingborg/>

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Friday 15th of October 2021 at 13.00 (CET).

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se